New drug BW-50218 begins first human safety tests
NCT ID NCT07401472
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing the safety and tolerability of a new drug called BW-50218 in 60 healthy adults. Participants receive a single injection of either the drug or a placebo, and researchers monitor for side effects and how the drug moves through the body. The goal is to gather basic safety information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BW-50218
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS STUDY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CMAX Clinical Research Pty Ltd
RECRUITINGAdelaide, South Australia, 5000, Australia
-
Linear Early Fhase Limited
RECRUITINGNedlands, Western Australia, 6009, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new experimental pill be safely given to people?
- Can a new injectable drug safely tackle weight? an early trial seeks answers
- Experimental biologic CND319 takes first steps toward taming autoimmune diseases
- Scientists map brain changes during Hour-Long DMT experience
- First human trial launches for experimental drug BY002
- New drug BW-50218 put to first safety test in healthy chinese volunteers